Dr. Mayo began working on cyclophilin in 1983 and has 20 years of experience in the pharmaceutical industry. His work across all phases of drug development, from pre-clinical to Phase 4 post-marketing surveillance, has been instrumental in regulatory submissions including INDs and NDAs. He has direct hands-on expertise in pre-clinical and clinical pharmacology, drug discovery, population pharmacokinetics/pharmacodynamics (PK/PD), and physiologically-based modelling.
Dr. Mayo’s work has focused on calcineurin inhibitors cyclosporine, tacrolimus and voclosporin, an analogue of cyclosporine. He began his career in the pharmaceutical industry as a clinical research organization kineticist, where he worked extensively on cyclosporine, including the reformulation of cyclosporine, Neoral™. Most recently, Dr. Mayo published on the population PK/PD of tacrolimus and mycophenolic acid in renal allograft patients and provided population PK modelling and simulation support for Aurinia Pharmaceuticals Phase 2 voclosporin study in lupus nephritis. He also provided PK analyses of early cyclophilin inhibitors developed by Ciclofilin Pharmaceuticals. In addition, Dr. Mayo was the Director of Clinical Pharmacology for Isotechnika during the Phase 1 through Phase 3 work on voclosporin in renal transplantion and plaque psoriasis.
Dr. Mayo obtained his PhD in pharmacokinetics from the University of Alberta, specializing in the effect of disease states on PK/PD relationships. He holds a BSc degree in pharmacy from the University of Alberta, where he worked as a clinical pharmacist in critical care, palliative care, and renal transplant. Dr. Mayo continues to provide pharmacometric analyses via Cogitare Analytics, and is the author, or co-author, of numerous scientific papers, abstracts and book chapters.
View in org chart
View in org chart